Evidence from recent human clinical trials supports the use of targeted therapies for five molecular subtypes of breast cancer based on the presence/absence of estrogen receptors (ERs) and progesterone receptors (PRs) and ERRB-2 (HER2) expression (6). This evidence concerns the gene ERBB2 and breast carcinoma.